FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016016828> ?p ?o ?g. }

• W2016016828 endingPage "S15" @default.
• W2016016828 startingPage "S9" @default.
• W2016016828 abstract "The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide were limited to myelosuppression and a response rate of 72% was seen in relapsed/refractory patients. Three phase II studies subsequently evaluated the efficacy of single-agent lenalidomide or lenalidomide in combination with dexamethasone. As a single agent for post-transplant salvage therapy, lenalidomide 25 mg every 3 weeks has shown response rates as high as 44%. For patients with relapsed/refractory multiple myeloma, the MM-007 study has shown that lenalidomide alone or in combination with dexamethasone provides response rates between 37% and 41%. In MM-007, median progression-free survival was 5.5 months at early analysis and the median overall survival has yet to be reached. Preliminary data for the single-arm, multicenter, open-label MM-014 study showed that median time to progression was 5.6 months. Response rates indicate that 70% of patients had stable disease or better as the best response to treatment. Two randomized, phase III trials (MM-009 and MM-010) evaluated lenalidomide with high-dose dexamethasone versus high-dose dexamethasone alone for the treatment of relapsed/refractory multiple myeloma. Both MM-009 and MM-010 provided remarkably similar response rates for patients receiving lenalidomide and dexamethasone. In both trials response rates with the combination were greater than twice the response rates seen with high-dose dexamethasone alone. Indeed, an independent Data Monitoring Committee determined that both trials exceeded the prespecified efficacy value of P <.0015, recommending that the trials be discontinued and that lenalidomide be offered to patients on the dexamethasone arm of the trial if clinically indicated. Toxicities observed in studies of lenalidomide alone were low; the incidence of peripheral neuropathy was significantly lower than those noted in trials using thalidomide. Thrombocytopenia was a significant grade 3 or 4 toxicity observed; however, it was manageable with dose reduction. In contrast with high-dose dexamethasone, deep vein thrombosis has emerged as an important toxicity. Lenalidomide is currently being tested in combination with both standard and novel agents, including bortezomib, for patients with relapsed/refractory multiple myeloma." @default.
• W2016016828 created "2016-06-24" @default.
• W2016016828 creator A5043526996 @default.
• W2016016828 date "2005-10-01" @default.
• W2016016828 modified "2023-10-10" @default.
• W2016016828 title "Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide" @default.
• W2016016828 cites W1978377409 @default.
• W2016016828 cites W2064114299 @default.
• W2016016828 cites W2065718044 @default.
• W2016016828 cites W2066936999 @default.
• W2016016828 cites W2133986577 @default.
• W2016016828 cites W2144531125 @default.
• W2016016828 cites W2316160054 @default.
• W2016016828 cites W2559630434 @default.
• W2016016828 cites W4313376856 @default.
• W2016016828 doi "https://doi.org/10.1053/j.seminhematol.2005.10.004" @default.
• W2016016828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16344100" @default.
• W2016016828 hasPublicationYear "2005" @default.
• W2016016828 type Work @default.
• W2016016828 sameAs 2016016828 @default.
• W2016016828 citedByCount "13" @default.
• W2016016828 countsByYear W20160168282012 @default.
• W2016016828 countsByYear W20160168282022 @default.
• W2016016828 crossrefType "journal-article" @default.
• W2016016828 hasAuthorship W2016016828A5043526996 @default.
• W2016016828 hasConcept C126322002 @default.
• W2016016828 hasConcept C141071460 @default.
• W2016016828 hasConcept C142424586 @default.
• W2016016828 hasConcept C143998085 @default.
• W2016016828 hasConcept C2776063141 @default.
• W2016016828 hasConcept C2776364478 @default.
• W2016016828 hasConcept C2776694085 @default.
• W2016016828 hasConcept C2779609412 @default.
• W2016016828 hasConcept C2780401358 @default.
• W2016016828 hasConcept C2780775027 @default.
• W2016016828 hasConcept C31760486 @default.
• W2016016828 hasConcept C535046627 @default.
• W2016016828 hasConcept C71924100 @default.
• W2016016828 hasConcept C86803240 @default.
• W2016016828 hasConcept C87355193 @default.
• W2016016828 hasConcept C90924648 @default.
• W2016016828 hasConcept C98274493 @default.
• W2016016828 hasConceptScore W2016016828C126322002 @default.
• W2016016828 hasConceptScore W2016016828C141071460 @default.
• W2016016828 hasConceptScore W2016016828C142424586 @default.
• W2016016828 hasConceptScore W2016016828C143998085 @default.
• W2016016828 hasConceptScore W2016016828C2776063141 @default.
• W2016016828 hasConceptScore W2016016828C2776364478 @default.
• W2016016828 hasConceptScore W2016016828C2776694085 @default.
• W2016016828 hasConceptScore W2016016828C2779609412 @default.
• W2016016828 hasConceptScore W2016016828C2780401358 @default.
• W2016016828 hasConceptScore W2016016828C2780775027 @default.
• W2016016828 hasConceptScore W2016016828C31760486 @default.
• W2016016828 hasConceptScore W2016016828C535046627 @default.
• W2016016828 hasConceptScore W2016016828C71924100 @default.
• W2016016828 hasConceptScore W2016016828C86803240 @default.
• W2016016828 hasConceptScore W2016016828C87355193 @default.
• W2016016828 hasConceptScore W2016016828C90924648 @default.
• W2016016828 hasConceptScore W2016016828C98274493 @default.
• W2016016828 hasLocation W20160168281 @default.
• W2016016828 hasLocation W20160168282 @default.
• W2016016828 hasOpenAccess W2016016828 @default.
• W2016016828 hasPrimaryLocation W20160168281 @default.
• W2016016828 hasRelatedWork W1974135782 @default.
• W2016016828 hasRelatedWork W1980068016 @default.
• W2016016828 hasRelatedWork W2022036807 @default.
• W2016016828 hasRelatedWork W2030475312 @default.
• W2016016828 hasRelatedWork W2041042375 @default.
• W2016016828 hasRelatedWork W2058009067 @default.
• W2016016828 hasRelatedWork W2118465399 @default.
• W2016016828 hasRelatedWork W2362389383 @default.
• W2016016828 hasRelatedWork W2462844398 @default.
• W2016016828 hasRelatedWork W3042537788 @default.
• W2016016828 hasVolume "42" @default.
• W2016016828 isParatext "false" @default.
• W2016016828 isRetracted "false" @default.
• W2016016828 magId "2016016828" @default.
• W2016016828 workType "article" @default.